🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
2.450
-0.270 (-9.93%)
At close: Nov 20, 2026, 4:00 PM EST
2.509
+0.058 (2.39%)
After-hours: Nov 20, 2026, 7:59 PM EST
← View all transcripts

Jefferies Global Healthcare Conference

Nov 18, 2026

Summary

REC-4881 showed durable polyp reductions in FAP, and FDA alignment was reached on its registrational endpoint, with study start planned for 2027. REC-1245 showed partial responses in heavily pretreated cancers; early expansion data are expected in H2 2027.

Dennis Ding
Analyst, Jefferies

All right. Good afternoon. Welcome to the Jefferies Healthcare Conference in London. My name is Dennis Ding, biotech analyst here at Jefferies. I have the wonderful pleasure of having Recursion Pharmaceuticals here. We have CEO Najat Khan here. Welcome.

Najat Khan
CEO, Recursion Pharmaceuticals

Thank you. Thank you so much.

Dennis Ding
Analyst, Jefferies

So I think there is obviously a lot going on. A lot has happened in 2026. Maybe just give us a brief overview, and also you guys had some updates this morning around the FAP program and just--

Najat Khan
CEO, Recursion Pharmaceuticals

Yeah.

Dennis Ding
Analyst, Jefferies

--the phase III. So why don't we start there, and then we will kind of pivot over to FAP.

Najat Khan
CEO, Recursion Pharmaceuticals

Sounds great. Again, great to be here. 2026 has been a big year for us. I mean, just starting the year, one of the areas that was a big focus is to be a company that is using AI to really, truly put points on the board for making differentiated medicine. I think what you see across whether developing novel targets, novel molecules, and then actually data in the clinic, we've kind of built that entire arc. I'll start maybe first with what's in the clinic. We have two first-in-class programs that have both shown positive data. Both came from our platform. First one is REC-4881.

This is our oral therapy for FAP, and we just had additional phase II data where we showed significant polyp burden reductions, also reductions that are durable, and when patients are off drug for up to three months, and really, really deep reductions of the polyps both in the upper and lower GI. The upper GI has been a huge area of unmet need from previous efforts in the space. I will also say we just had an update this morning, which is really exciting in terms of alignment with the FDA on our registrational phase III study. This is a base case was always a composite endpoint. That's been the precedence, but we actually have a novel component in that composite endpoint, which is the excision of 10 or greater than 10 mm of polyps, and happy to talk more about that.

One thing to note is, this is a disease with no approved therapies. So talk about having an AI-enabled program that is slated for registrational study, and there's a few, but there's none that's actually being done for diseases where there's no approved therapies. I think that's one. Second, we also have positive data from REC-1245, which is RBM39. This is also a first-in-class program where the target, the degrader molecule, and the indications we went into were defined by our platform. I like to call it that trifecta. We just shared some early monotherapy data there as well. Three PRs, two confirmed PRs in endometrial cancers patients, and one in HCC, heavily pretreated. That's just the two programs that we have, both first in class, where we've shown positive data. In addition to that, we've also had some great progress with our partners.

We have designed a novel first-in-class oral INI molecule using our platform that was just optioned in by Sanofi a few weeks ago. That's again a great example of can our engine actually develop molecules that are first in class? Really hard to do. It's actually a dual inhibitor, which means it's a small molecule hitting two targets at the same time. Each of those programs have milestones of about $343 million and double-digit royalties. Last but not the least, we have also shown that we can derive novel causal targets from our platform. We have these large proprietary maps of biology we've created, and in partnership with Roche Genentech, kudos to the joint teams, they've actually optioned in novel targets from our maps and showcased that in their investor days as well.

What you are seeing big picture is, at the end of the day, if you are using AI to make differentiated medicines, you want to show positive data in the clinic and in diseases where the patients are highly refractory or there is nothing approved. We have done that. In addition to that, with our partners, we have just crossed about $535 million in cash inflows, 9-10 milestones just in the last 18 months or so. That showcases the ability for us to do novel targets, novel molecules, and positive clinical data in a repeatable engine, and that is why we built the company the way we did. Last thing I will say is we are doing all of this, and we have reduced our burn by 40%. It is really important to be disciplined, and quite frankly, our engine is also getting more productive, and I will walk through some of those examples. Again, thank you.

We recently did an oversubscribed round as well with a lot of great investors joining us from the biotech institutional investors and also tech investors. A lot that has been done, and a lot of this progress really has been in the second half of this year. Can't wait for the Christmas break.

Dennis Ding
Analyst, Jefferies

Fantastic. Me too. If we can kind of focus on FAP, that is not necessarily an opportunity that most people are familiar with. Just remind us, just sort of like the TAM, the opportunity--

Najat Khan
CEO, Recursion Pharmaceuticals

Yep

Dennis Ding
Analyst, Jefferies

--the burden, and also what your phase III design, which you guys just announced this morning, kind of, how is that going to be able to capture some of the benefit from your asset?

Najat Khan
CEO, Recursion Pharmaceuticals

Yeah. That's a great question. I'll start with the disease because I think people are increasingly getting familiar with FAP. I mean, when I used to talk about it last year, there was a lot of question marks, but that kind of momentum and interest has changed dramatically. FAP is a rare disease. It's driven by a loss of function in the APC gene, and essentially what you end up getting are patients that have hundreds of polyps in their colon, upper GI, so duodenum, rectum, and so forth. There is nothing approved to date. The TAM is about $15 billion. That includes greater than 50,000 patients in the U.S. and EU5. Standard of care today is a patient that's about 10 years, adolescence, they end up getting colectomy, so the colon is removed.

But 80%-90% of the patients, the polyps keep growing in their upper GI, their duodenum, and then also in the rectum. Essentially what happens is intense surveillance, tons of excisions, lots of interventions, and also life-altering surgeries, such as removing parts of the duodenum, removing parts of the rectum, and so forth. So, a very, very horrific and challenging disease with nothing approved to date. When these patients are post-colectomy, think about it, they're living five to six decades of this chronic disease where more and more of their anatomy is being removed because of the really progressive nature of this disease. Every single polyp here is, of course, precancerous. In terms of what we have done to date, maybe just a little bit on that and then the phase III.

What we've shown in our phase II, post-colectomy patients, they're actually about one in three are seeing greater than 65% reduction in the polyp burden, so this is size and number, in just 13 weeks. So that's one of the most rapid reduction in polyps shown to date. Then we see really nice reduction in both the upper and lower GI. I mention that for a reason. Post-colectomy, the colon is gone, so a lot of the disease exists in the upper GI. Very thin lining, hard to remove these polyps, there's a lot of bleeding, perforation. In addition to that, also, of course, in the rectum, rectal pouch, and so forth. Big area of unmet need. We are one of the very few that have actually shown reduction in the upper GI polyp burden and also the lower GI polyp burden.

Interestingly enough, we were just at the CGA conference, which is the conference for a lot of these inherited GI syndromes, and the physicians are there, surgeons are there, and so forth. What you're seeing is that even when the patients are followed for three months off drug, most of the reduction is sustained. We believe that's potentially happening because the allosteric MEK1/2 inhibitor is actually hitting dual pathways, both the MAPK, which is expected, of course, and these polyps accumulate mutations, KRAS, BRAF, and so forth, but also via crosstalk via KITENIN. So, that's a really exciting feature for an asset and a therapeutic that patients will be taking for many, many decades, potentially. In addition to that, we've actually seen a couple of patients with near clearance of the disease after 13 weeks.

Where we are right now is we just shared this morning that we have aligned with the FDA on a pivotal registrational primary endpoint. This is a time-to-event endpoint, which has always been the precedence in this case, which is time to the first event. That can be time to dysplasia in the polyp, that can be time to the need for surgery, and there is many, a litany of surgeries there, and also cancer and death. In addition to that, we were able to align on adding a novel component to the composite endpoint, which is the excision of greater than or equal to 10 mm polyps anywhere throughout the GI. It can be upper or lower GI. The significance of that is for the following reasons.

Number one, polyps that are greater or equal to 10 mm are the ones that are known to have higher risk of dysplasia and cancer. Number two, it is hard to remove them. There is risk of perforation, bleeding, and often also incomplete removal of the polyp. And third is, it is actually something that is routinely done in the FAP care. So it is not something that is a new measurement or something that needs a lot of education. It is actually part of the AGA guideline as well. This, we believe, from a clinical meaningfulness, obviously it is very clinically meaningful, and also it will help us from an event accrual rate as well, given this is an event-driven study. The patient population would be 18 and over, post-colectomy. And also there has been a pre-specified interim analysis that will also be incorporated as part of this.

A lot of hard work on this front. We are slated to start the registrational study next year, and we will give more guidance on that.

Dennis Ding
Analyst, Jefferies

Perfect. Maybe I can summarize that a little bit. In FAP, patients have hundreds of polyps.

You guys reduce the polyps, and when you reduce the polyps, you kind of prevent some of these things from happening, like colectomy and excision and all that kind of stuff. That is what you are measuring in your phase III, right?

Najat Khan
CEO, Recursion Pharmaceuticals

Yeah.

Dennis Ding
Analyst, Jefferies

You have confidence that given what you have seen in phase II, I think 50%-60% polyp reduction, both lower and upper GI, that should translate to fewer of these events.

Najat Khan
CEO, Recursion Pharmaceuticals

Yeah, it is a really important point. The central node for the surgeries, the central node for dysplasia, the central node for excisions, all of this that is happening is driven by polyps. That is the reason why all of this is happening downstream. So if you can actually reduce the polyps, you reduce the potential need for surgery. I will give you an example. Actually, in our phase II, we had a patient that had 96 greater than 5 mm upper GI polyps that reduced to one after 13 weeks. That patient with over 96 polyps would have met the criteria for surgery, and with one polyp, they do not meet the criteria for surgery. So that is just one example in terms of how you can change sort of the trajectory of the disease altogether. Therefore, exactly.

The central node is always the polyps, and all of these are downstream of that. That is why the excision piece was really important for us to incorporate, because these patients, just to give you a sense, these patients are going under for complex endoscopies, polyp removals, et cetera, multiple times a year often. So this is a highly invasive, life-altering, and intensive disease. Patients also suffer a ton of medical PTSD in terms of waiting for the other shoe to drop. What else are they going to find? For all of those reasons, we feel good about what we have.

Dennis Ding
Analyst, Jefferies

When you think about the primary endpoint, I mean, it seems like it's an event-driven study.

Najat Khan
CEO, Recursion Pharmaceuticals

Yeah.

Dennis Ding
Analyst, Jefferies

I'm assuming that you guys have to reach a certain number of events at the end of the study in order to trigger the actual top line or the final analysis. How do you model out that event rate? What kind of data do you guys have to do that, because that's going to impact how you're powering the study as well.

Najat Khan
CEO, Recursion Pharmaceuticals

Yeah. So a few things. Look, I mean, with a rare disease, there's some natural history, but nothing's ever perfect. We've done a lot in terms of using our AI tools to really understand the contemporaneous nature of the disease. For instance, we have access to about 300 million patient lives, physician notes, so we've scraped a lot of that, about 256,000 notes, which covers about 1,000 patients, just to understand what's the real learning of how the patients are being treated today, what are the big challenges, such as large polyps, such as all of the invasive life-altering surgeries that are happening. Back in the day, people thought that you do post-colectomy and you're fine. You are not fine. You're far from fine. So that's been part of it. Of course, we also do, of course, a lot of simulations internally.

But I will say there's two, three things that are going to be important here. One, recruitment is going to be important, right? With any rare disease, and also, for instance, any event-driven study, that's going to be a huge part of where we use our AI platform as well in order to find the right sites for our patients. That's one. The second is going to be also how we the endpoint that we have. Again, this is why endpoints and components that we feel have the potential to at least help us accrue events was important, which is why the news today is so important. The third is also the patient, the inclusion/exclusion criteria, so we'll be very thoughtful about that. A lot of that has been factored in, and we're looking forward to getting started next year.

Dennis Ding
Analyst, Jefferies

Got it. For the interim, which I think is fairly interesting, is there any kind of preliminary thinking around what that interim would look like in terms of how many events, maybe even help us understand the timing of the interim?

Najat Khan
CEO, Recursion Pharmaceuticals

Yeah. Look, I think the interim is really important, and we were great. That was an upside in order to have that as part of our plan. We haven't given guidance on the details of it, but you can imagine, as you said, it's an event-driven study, so it will be dependent on a certain number of events. Again, we'll share more as we progress through, but it was definitely a great aspect to have in our study.

Dennis Ding
Analyst, Jefferies

You guys have committed to start studying the second half of 2027. That's about a year from now. What is there left to do, either with the FDA or just internally, that you guys have to do until you start the study?

Najat Khan
CEO, Recursion Pharmaceuticals

Yeah. We'll give more refinement of the timeline in terms of second half. I wouldn't assume it's a whole year from now.

In addition to that, what I will say, look, this is going to be a global registrational study. We feel good in terms of patient population, endpoint, and so forth, in terms of the conversations we've had with the FDA. A lot of it is just going to be getting the study started. Those are the main things that we're focused on.

Dennis Ding
Analyst, Jefferies

Perfect. Let's switch over to your second product in the clinic, that targets RBM39.

Just remind us of some of the data that you guys have shown recently, and some of the partial responses that you had.

Najat Khan
CEO, Recursion Pharmaceuticals

Yeah, and maybe just because it is a first-in-class program and a novel target, I'll just say a little bit about the mechanism.

Dennis Ding
Analyst, Jefferies

Sure.

Najat Khan
CEO, Recursion Pharmaceuticals

Just to anchor as to why the program is the way it is. RBM39, it's an important target when it comes to splicing fidelity. And a lot of solid tumors, especially ones that are genomically unstable, they rely on really good and high-fidelity RNA processing. So, it is a backbone mechanism that can be relevant across multiple solid tumors. So we're looking at it both from a monotherapy and potential combo approach as well. What we've shared so far is we did monotherapy dose escalation, and what we've seen, which was an upside for us, is actually three PRs, two confirmed PRs and one unconfirmed PR, two in very heavily pre-treated endometrial cancer patients, post-sac-TMT even in some cases, and also one unconfirmed PR in HCC.

What we're doing right now is actually focusing on the next stage, which is expansion cohorts in endometrial and some other solid tumors as well. The reason why this is of interest is, number one, the target was actually identified using our large maps of biology. The degrader was designed using our platform, and then, of course, we see the data. In the clinic, we had over-indexed in recruiting endometrial cancer patients because of some of the work that we had done internally that pointed to the potential for response there. What I will say is, in the endometrial cancer patients, we had a couple of them, both of them that had confirmed PRs, about fifth, sixth, even seventh line, so heavily pre-treated. And we've seen reductions of unconfirmed PR first, and then deepening further to confirmed PR.

So one of the patients went down to 50%, tolerating the dose well. So we had very little grade three, with one or two that were resolved on their own. Other than that, mostly grade one, two anemia and fatigue. So, so far tolerating well. So we're circling around the 45 mg QD dose. And yeah, we feel really good about what we're seeing. The other thing I would say is, in terms of combo, RBM39 is a unique MOA and pretty synergistic to ADCs and others that we'll see there. So there's also the potential for combinations that we will explore. Our beachhead would be in endometrial, but again, there are other solid tumors that we'll explore as well. We will have more data on the endometrial expansion cohort second half of next year.

Dennis Ding
Analyst, Jefferies

Can you talk a little bit more about RBM39 as a mechanism? And we've kind of--

Najat Khan
CEO, Recursion Pharmaceuticals

Yes.

Dennis Ding
Analyst, Jefferies

--talked about this before, around whether it is a cytotoxic mechanism like chemo or cytostatic mechanism. Just remind us of that, and did the PRs that you saw, was that surprising given your understanding of the RBM39 biology?

Najat Khan
CEO, Recursion Pharmaceuticals

Yeah. I mean, we have talked about this before. I think it is a little bit of both. I will say it was surprising in the sense that these patients are heavily pre-treated. They are fifth, sixth, seventh line. So, they have progressed on the latest TROP2 ADCs. One of the patients had even progressed on an investigational CAR T therapy. So they are very, very late-line patients. So, being able to see confirmed PR in that patient population was a good upside and a pleasant surprise. But we were always, of course, considering combo potential there as well.

I think the other thing to note is so far what we see from a tolerability profile is manageable, and that is also, if we do not have overlapping tox and so forth with some of the other things that we would combine with, like ADCs or IOs, et cetera, potentially, that also gives us confidence and the flexibility of what we can do with this asset.

Dennis Ding
Analyst, Jefferies

Okay. Endometrial expansion cohort has started. We are going to get an update on that in the second half of 2027.

Najat Khan
CEO, Recursion Pharmaceuticals

Yeah.

Dennis Ding
Analyst, Jefferies

How should we think about the, I guess, how robust that data update will be? Meaning, are we going to get 20 patients and it's one-year data or it's even six-month data, or is it going to be like five, six, seven, and we're still kind of trying to tease out the signal?

Najat Khan
CEO, Recursion Pharmaceuticals

Yeah. We're recruiting for that cohort right now, and we said it would be early expansion cohort data. You can imagine, if it's second half of 2027, we'll have a handful of patients. Again, what we're looking for is that continued signal that we have seen to date.

Dennis Ding
Analyst, Jefferies

Okay.

Najat Khan
CEO, Recursion Pharmaceuticals

In parallel, of course, we're also exploring a couple of other solid tumors as well. We even disclosed that, and also assessing the combo potential. More to come.

Dennis Ding
Analyst, Jefferies

Okay. Because when I think about late-line endometrial, and I think you guys just started the expansion cohorts, right? When we think of it doesn't seem like this is the type of MOA that drives a really high ORR, right? Because it's not necessarily cytotoxic. We should really be looking at maybe DOR or PFS, right? Do you think second half 2027, by the time we get there, by the time you enroll patients, maybe we'll get six months PFS, or do you think that's long enough to actually get a PFS signal that's differentiated relative to chemo?

Najat Khan
CEO, Recursion Pharmaceuticals

Yeah. I would just say right now, we are just starting it. Our focus is let us get the patients on, let us see what the activity is. If we see anti-tumor activity like we have seen, we saw two confirmed PRs, two almost PRs, they were in the mid-20s, and then out of the last cut, it was eight patients or so. That was pretty encouraging to see. More to come, Dennis.

Dennis Ding
Analyst, Jefferies

We are always trying to think ahead.

Najat Khan
CEO, Recursion Pharmaceuticals

I know.

Dennis Ding
Analyst, Jefferies

Maybe too far ahead.

Najat Khan
CEO, Recursion Pharmaceuticals

Think but not say.

Dennis Ding
Analyst, Jefferies

Okay. In our discussion about RBM39, I think you mentioned the word combo like 10 times, right?

Najat Khan
CEO, Recursion Pharmaceuticals

Today?

Dennis Ding
Analyst, Jefferies

Yeah.

Najat Khan
CEO, Recursion Pharmaceuticals

Hmm. Interesting.

Dennis Ding
Analyst, Jefferies

I mean, the last 20 minutes.

Najat Khan
CEO, Recursion Pharmaceuticals

I thought it was four.

Dennis Ding
Analyst, Jefferies

So, just help us understand that because you guys will have monotherapy, you guys will eventually pivot to combo. I guess, how are you thinking about what is a right partner to combo with, in terms of mechanism?

Najat Khan
CEO, Recursion Pharmaceuticals

I see. Look, it depends on the indication. Of course, you can imagine who would be certain ones I've mentioned, ADCs maybe five times. Here's what I would say. Look, we look at the monotherapy profile. Post-ADCs, there's still pretty significant unmet need in endometrial cancer. The ORR is still in the, now maybe in the mid-30s or so, but even then, there's a lot of unmet need there. From a combo perspective, there's many different areas we can go in, but we'll let data drive us as to where we go, whether it's ADCs, IOs, or other areas.

Dennis Ding
Analyst, Jefferies

Okay. I think you mentioned both of your PRs in endometrial were post-sac-TMT.

Najat Khan
CEO, Recursion Pharmaceuticals

Yeah.

Dennis Ding
Analyst, Jefferies

Right?

Najat Khan
CEO, Recursion Pharmaceuticals

Post-TROP2 ADCs, one was post-sac.

Dennis Ding
Analyst, Jefferies

Okay. Got it. Perfect. How should we think about the toxicity profiles between, let's call it sac-TMT or some of these other TROP2s versus your drug?

Najat Khan
CEO, Recursion Pharmaceuticals

Yeah, that is what I was saying. What we see so far, majority is grade one, two, at the dose of 45 mg QD, and essentially, it is mostly what we are seeing is fatigue and anemia.

Dennis Ding
Analyst, Jefferies

Okay. Perfect. I think what is super interesting about this drug, and you kind of touched on this earlier, is that from end to end, from target validation to drug synthesis, you guys leverage AI. I think that is a little bit slightly different than your MEK inhibitor, right? You guys did use AI, but that product did not come, it was not a de novo compound.

Najat Khan
CEO, Recursion Pharmaceuticals

Yeah. Just to maybe, it's a good distinction to make. For REC-4881, the insight was really around the unappreciated, unknown synthetic rescue of APC loss of function by a MEK1/2 inhibitor. The biological insight. Look, prior to Recursion, I wouldn't have considered a MEK1/2 inhibitor for FAP. I wouldn't have anticipated that. That insight, which came from our platform, taking cells, knocking out the APC gene where the morphology is different, and actually using our AI foundation models to screen compounds and say which one reverses it from disease to healthy, I think there's alpha there. That is an insight that others wouldn't have gone after. The biology part of the platform was used for MEK1/2, and then, of course, now the clinical development, the IPs for all the reasons we talked about.

To your point, for the REC-1245, the target, the molecule, which is a degrader, and also which patient populations we should over-index are all coming from. That's what you see with the maturation of the platform, because it's only in the last 12 to 18 months where we've really expanded and built out the engine. Because to me, it's really important. It's not just a nice cute assay, which is important from research or scientific or academic purposes, but it's actually something that can build novel targets, design the molecule, and show you data in the clinic. That's a true AI-native R&D engine.

Dennis Ding
Analyst, Jefferies

Got it. As we look into 2027, you guys will start the phase III in the second half for FAP. We'll get some early expansion data.

Najat Khan
CEO, Recursion Pharmaceuticals

Yeah.

Dennis Ding
Analyst, Jefferies

I heard you. Early expansion data for--

Najat Khan
CEO, Recursion Pharmaceuticals

Monotherapy-

Dennis Ding
Analyst, Jefferies

--monotherapy-

Najat Khan
CEO, Recursion Pharmaceuticals

monotherapy. Just to say that.

Dennis Ding
Analyst, Jefferies

--in second half. What else can we expect from Recursion in the pipeline, et cetera?

Najat Khan
CEO, Recursion Pharmaceuticals

Yeah. Great question. So we have a couple of additional programs too, such as LSD1. We also have a brain penetrant LSD1 inhibitor that should have some data as well, second half of next year. We have additional programs in our pipeline, couple of other ones. We have an oral ENPP1 inhibitor, an IND enabling. So multiple, that's the nice thing about it. We have two first-in-class programs that we spend a lot of time about, but there's also three or four programs behind that that are also maturing and have data. So that's number one. Number two, we'll also make more progress on the partnerships. Dennis, I want to make sure we mention that as well. For instance, with Sanofi, we have additional milestones. I mentioned the oral INI that they had optioned molecule that we had developed using a platform that they had optioned in.

There's potential for more milestones there as well with additional programs. And with Roche Genentech, we also have additional milestones there in terms of novel targets, in addition to the ones that they optioned already in neuroscience and GI onc. And we're actually now not just producing the novel targets, but designing those molecules as well for those targets using our platform. So you see the maturation of those partnerships as well.

Dennis Ding
Analyst, Jefferies

Perfect. Maybe in the last minute, what do you think investors are underappreciating or missing about Recursion?

Najat Khan
CEO, Recursion Pharmaceuticals

I think the company has evolved a lot in the last 12 to 18 months, so I think there's a little bit of catch-up in terms of who Recursion is. I remember January to March was a lot of, "Who is Recursion? What does Recursion actually focus on?" I think you've seen that again with our raise as well. Really grateful to some very blue chip investors who've joined us, that we're a serious contender in terms of making differentiated medicines with a clear link as how you use AI to do it. Not just a one-off, we're not a single asset company, but to do it in a repeatable way, which is why I think the partnerships matter.

Because a lot of people talk about doing deals, but it's very As somebody that's really smart said to me, "Promises are easy to make, harder to deliver on." That's been our focus. I think that whether it's our FAP program, which FAP was not on people's radar until it really started this year with the type of the data that we're seeing and the repeatability of the engine, I think there is a lot more that can be appreciated in terms of what Recursion is doing. Last thing that I'll say is, we're in November, but all of the milestones that we had committed to this year, we have achieved and gone over, above and beyond. I think that's also really important, sort of the say-do philosophy, that you commit to things and you deliver on time.

We're getting good reps on our belt to do that, but I would love to see more appreciation of that.

Dennis Ding
Analyst, Jefferies

Fantastic. Well, thank you so much for the time, Najat, and i t's a great discussion and hope you have a great conference.

Najat Khan
CEO, Recursion Pharmaceuticals

Thank you. Thanks so much.